Skip to main content

1 Result(s)

within Alex Ambinder Remove this filter

and

  1. Article

    Open Access

    Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification

    Secondary AML (sAML), defined by either history of antecedent hematologic disease (AHD) or prior genotoxic therapy (tAML), is classically regarded as having worse prognosis than de novo disease (dnAML). Clinic...

    Michael J. Hochman, Megan Othus, Robert P. Hasserjian, Alex Ambinder… in Leukemia (2023)

    Download PDF (512 KB) View Article